A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 78
[Display Entries]
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : KRAS
Long Form : Kirsten Ras
No. Year Title Co-occurring Abbreviation
2020 A H-REV107 Peptide Inhibits Tumor Growth and Interacts Directly with Oncogenic KRAS Mutants. GDP, GTP
2020 Associations between nutritional factors and KRAS mutations in colorectal cancer: a systematic review. CRC
2020 Clinico-Pathological Study of K-ras Mutations in Colorectal Tumors: A Single-Center Retrospective Study of 51 Patients in Madinah, Saudi Arabia. CRC, RAS
2020 Magnetic Resonance-Based Texture Analysis Differentiating KRAS Mutation Status in Rectal Cancer. MR
2020 Preoperative prediction of perineural invasion and KRAS mutation in colon cancer using machine learning. PNI
2020 Proof of concept for poor inhibitor binding and efficient formation of covalent adducts of KRASG12C and ARS compounds. ---
2020 Role of Poly [ADP-ribose] Polymerase 1 in Activating the Kirsten ras (KRAS) Gene in Response to Oxidative Stress. 8OG
2019 Association between oncogenic RAS mutation and radiologic-pathologic findings in patients with primary rectal cancer. ADC, AUC, LTLs, MRI, SI
2019 Colorectal cancer patients in western Saudi Arabia. Outcomes and predictors for survival over a 10-years period (2002-2014). CRC
10  2019 CRNDE promotes cell tongue squamous cell carcinoma cell growth and invasion through suppressing miR-384. CRNDE, lncRNAs, TSCC
11  2019 Emergence of KRAS p.G13D mutation and acquired resistance to cetuximab in colorectal cancer with vulvar metastasis: A case report. CRC, PET-CT
12  2019 Lung Metastasis Predicts Better Prognosis in Metastatic Colorectal Cancer With Mutated KRAS. CEA, CI, HR, mCRC
13  2019 Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants. EGFR, ERK, NRAS
14  2019 The Hippo Signaling Pathway in Pancreatic Cancer. TAZ, YAP
15  2018 Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates. EGFR, RAS
16  2018 The regulatory G4 motif of the Kirsten ras (KRAS) gene is sensitive to guanine oxidation: implications on transcription. 8-oxoG
17  2017 Mutational analysis of the RAS/RAF/MEK/ERK signaling pathway in 260 Han Chinese patients with cervical carcinoma. ERK, ERK2, MAPK1, MEK, RAS
18  2017 RNA G-Quadruplexes in Kirsten Ras (KRAS) Oncogene as Targets for Small Molecules Inhibiting Translation. ---
19  2017 The Association Between HSP90/topoisomerase I Immunophenotype and the Clinical Features of Colorectal Cancers in Respect to KRAS Gene Status. CRC, Hsp90, topo I
20  2016 Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutations. EGFR
21  2016 EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients. EGFR, HIV, HR, NSCLC
22  2016 KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study. LLD, mCRC, OS, PFS
23  2016 KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer. EPSCC, NSCLC, SCLC
24  2016 MiR-384 inhibits human colorectal cancer metastasis by targeting KRAS and CDC42. Cdc42, CRC
25  2016 Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. CRC, EGFR
26  2016 Prediction of KRAS Mutation in Rectal Cancer Using MRI. MRI
27  2016 Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. PD-L1, SC
28  2015 Bone Metastases and the EGFR and KRAS Mutation Status in Lung Adenocarcinoma--The Results of Three Year Retrospective Analysis. QL, SRE
29  2015 Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer. CRC, OS, PFS
30  2015 K-Ras mutation and prognosis of colorectal cancer: a meta-analysis. CRC
31  2015 KRAS and BRAF mutations in anal carcinoma. EGFR
32  2015 Label-Free Raman Spectroscopic Imaging Monitors the Integral Physiologically Relevant Drug Responses in Cancer Cells. EGFR
33  2015 Peripheral lung adenocarcinomas with KRAS mutations are more likely to invade visceral pleura. ---
34  2015 Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients. CRC
35  2015 Targeting the RAS pathway by mitogen-activated protein kinase inhibitors. BRAF, HRAS, MEK, NRAS, RAS
36  2015 Tyrosine kinase receptor B (TrkB) expression in colorectal cancers highlights anoikis resistance as a survival mechanism of tumour budding cells. CI, CIMP, EMT, TrkB
37  2014 Dietary acrylamide intake and the risk of colorectal cancer with specific mutations in KRAS and APC. APC, CI, CRC, HR
38  2014 The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies. CRC, EGFR, mCRC, MoAbs, NRAS, OS, pts, WT
39  2013 Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function. AGP, RAS
40  2013 Can mutations of EGFR and KRAS in serum be predictive and prognostic markers in patients with advanced non-small cell lung cancer (NSCLC)? EGFR, NSCLC
41  2013 Dietary heme iron and the risk of colorectal cancer with specific mutations in KRAS and APC. APC, CRC
42  2013 KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. CI, CRC, HR, MSI
43  2013 NRAS mutant melanoma--undrugable? HRAS, NRAS, RAS
44  2013 Oncologists' attitudes toward KRAS testing: a multisite study. mCRC
45  2012 EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors? EGFR, SCAC
46  2012 Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials. CECOG, mCRC
47  2012 Unlabeled-probe high-resolution melting to detect KRAS codon 12 and 13 mutations in pancreatic adenocarcinoma tissues. HRM, PA
48  2011 Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer. CAPOX, TP53
49  2011 Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib. EGFR, H-Ras
50  2011 Epidermal growth factor receptor mutation in gastric cancer. EGFR, HRMA, TKIs
51  2011 Mutation analysis of KRAS prior to targeted therapy in colorectal cancer: development and evaluation of quality by a European external quality assessment scheme. ---
52  2011 Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. ---
53  2010 Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine. ---
54  2010 Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. EGFR, IGFR, mCRC, MoAbs, OS, VEGF
55  2010 Primary cell lines: false representation or model system? a comparison of four human colorectal tumors and their coordinately established cell lines. CRC, DCC
56  2010 Sensitive and specific KRAS somatic mutation analysis on whole-genome amplified DNA from archival tissues. FFPE, HRM, WGA
57  2010 The EGFR pathway as an example for genotype: phenotype correlation in tumor genes. EGFR
58  2009 Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. G12V
59  2009 Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. CRC, EGFR
60  2008 Genetic alterations of APC, K-ras, p53, MSI, and MAGE in Korean colorectal cancer patients. APC, CRC, MAGE, MSI
61  2008 K-ras mutation, HPV infection and smoking or alcohol abuse positively correlate with esophageal squamous carcinoma. ESCC, HPV, N-ras
62  2008 The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. CFC, ERK, HRAS, MAPK, PTPN11
63  2008 The role of molecular markers in predicting response to therapy in patients with colorectal cancer. ---
64  2007 Single base instability is promoted in vulvar lichen sclerosus. LS
65  2006 Molecular target-based therapy of pancreatic cancer. IL-24
66  2005 Characterization of the regulation and functional consequences of p21ras activation in neutrophils by antineutrophil cytoplasm antibodies. ANCA
67  2005 High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. EGFR
68  2005 The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. APC
69  2005 Transcription inhibition of oncogenic KRAS by a mutation-selective peptide nucleic acid conjugated to the PKKKRKV nuclear localization signal peptide. ---
70  2004 B-Raf is dispensable for K-Ras-mediated oncogenesis in human cancer cells. ---
71  2003 Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR. ---
72  2003 K-ras regulates the steady-state expression of matrix metalloproteinase 2 in fibroblasts. MMP-2, PI-3
73  2003 Polyamines as modifiers of genetic risk factors in human intestinal cancers. APC, NSAID, ODC, PPARgamma
74  2002 Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer. APC
75  2002 Papillary solid and cystic pancreatic tumor. Genetic prediction factors for malignancy: report of three cases. FHIT, PSCPT
76  1998 Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT. ---
77  1991 Detection of K-ras mutations in pancreatic and hepatic neoplasms by non-isotopic mismatched polymerase chain reaction. PCR
78  1990 Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. ---